FDA: Enzon's Abelcet makes unsubstantiated superiority claims

Share this article:
A flash card for Enzon's Abelcet makes unsubstantiated superiority claims and overstates its efficacy, the FDA says. A warning letter says the claims raise concerns because they suggest it is more effective than  demonstrated and encourage its use before other options, even though it is a second-line agent.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.